Predicting gefitinib responsiveness in lung cancer by fluorescence *in situ* hybridization/chromogenic *in situ* hybridization analysis of *EGFR* and *HER2* in biopsy and cytology specimens

Lorenzo Daniele,[1] Luigia Macrì,[1]
Marina Schena,[3] Diego Dongiovanni,[3]
Lisa Bonello,[2] Enrico Armando,[1] Libero Ciuffreda,[3]
Oscar Bertetto,[3] Gianni Bussolati,[1]
and Anna Sapino[1]

[1]Department of Biomedical Sciences and Human Oncology
and [2]Center for Experimental Research and Medical Studies,
University of Turin; and [3]Medical Oncology, Azienda Sanitaria
Ospedaliera San Giovanni Battista, Molinette, Turin, Italy

Abstract

In non – small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutational analysis is an excellent predictor of responsiveness to treatment with tyrosine kinase inhibitors, such as gefitinib. In up to 80% of NSCLCs, cytologic samples or endoscopic biopsies are the only specimens available for molecular analysis, but PCR amplification of DNA from small fixed and paraffin-embedded samples may create artifactual mutations. Fluorescence *in situ* hybridization (FISH) of *EGFR* and *HER2* has been proposed as an alternative method of analysis. This project aimed to determine the optimal scoring method for FISH or chromogenic *in situ* hybridization (CISH) assays when analyzing small NSCLC samples to predict response. FISH or CISH analysis of *EGFR* and *HER2* genes was done on 42 small samples derived from NSCLC patients treated with gefitinib. *EGFR* mutational analysis was done after quantity and quality controls of DNA. In seven of seven cases, a balanced increase in *EGFR* gene and chromosome 7 number was found to correlate with the presence of specific *EGFR* mutations. In addition, seven of seven cases with balanced *EGFR*/*HER2* polysomy and two of three cases with balanced *EGFR*/*HER2* trisomy responded to gefitinib (75% of responders). Instead, the EGFR mutations predicted only 7 of 12 (58%) of gefitinib-responsive patients. When only endoscopic biopsies or cytologic specimens are available, we propose using FISH/CISH for *EGFR* and *HER2* as the test of choice for selecting patients for treatment with gefitinib and to consider as negative predictive factor the absence of *EGFR*/*HER2* gene gain. [Mol Cancer Ther 2007;6(4):1223 – 9]

Introduction

Epidermal growth factor receptor (EGFR) is a prototypical member of the EGFR family that also includes HER2, HER3, and HER4. HER2 and HER3 are the preferential partners of EFGR in the process of heterodimerization and activation (1). EGFR is implicated in the development and progression of non–small cell lung cancer (NSCLC; ref. 1). Tyrosine kinase inhibitors (TKI), which selectively block the growth-stimulating effect of EGFR, such as gefitinib (ZD 1839 or Iressa) and erlotinib (OSI 774 or Tarceva), have been developed (2–4). These small molecules compete with and prevent the binding of ATP at its binding region within the EGFR tyrosine kinase domain, thereby inhibiting tyrosine phosphorylation and signaling events implicated in cell cycle progression, apoptosis, angiogenesis, and metastasis (5).

Several patient characteristics, such as never smokers, Asian ethnicity, female gender, and a histologic diagnosis of adenocarcinoma, are associated with increased responsiveness to EGFR TKIs (6, 7). Several approaches, including immunohistochemistry and gene mutation or copy number enumeration, have been tested to quantify EGFR protein or gene in tumor specimens to predict response to treatment. Immunohistochemistry is inadequate for discriminating responders from nonresponders, drawbacks, including the heterogeneity of anti-EGFR reagents and immunohistochemical methodologic approaches, and the diversity of immunohistochemical scoring methods (8). Somatic mutations in the *EGFR* kinase domain are correlated with gefitinib sensitivity (9–11). However, at the time of diagnosis, only about 20% to 25% of lung cancers can potentially be cured primarily by surgery, and samples from fine-needle aspiration or endoscopic biopsies of the lesion are the only specimens available for diagnosis and molecular analysis. Small samples may be inadequate to mutational studies because these analyses require significant amounts of tumor cell DNA to avoid contamination from unmutated wild-type DNA of normal cells and

Requests for reprints: Anna Sapino, Department of Biomedical Sciences and Human Oncology, University of Turin, Via Santena 7, 10126 Turin, Italy. Phone: 39-011-633-4274; Fax: 39-011-663-5267.
E-mail: anna.sapino@unito.it

Table 1. Type of specimens analyzed and *in situ* hybridization analysis of 42 cases of NSCLC

	n (%)	FISH	CISH
FFPE histologic specimens			
Surgical samples	13 (31)	13	
Endoscopic bronchial biopsies	20 (48)	20	
Cerebral biopsy	1 (2)	1	
Bone biopsy	1 (2)		1
Spinal biopsy	1 (2)		1
AFPE cytologic specimens			
Pleural effusion	2 (5)		2
Bronchial washing	1 (2)		1
Lung FNA	3 (7)	3	

Abbreviations: FFPE, formalin fixed, paraffin embedded; AFPE, alcohol fixed, paraffin embedded; FNA, fine-needle aspiration.

mutation artifacts can be observed when carrying out multiple PCR amplifications with very small amounts of DNA isolated from paraffin-embedded tissues (12). Recent reports have described the use of fluorescence *in situ* hybridization (FISH) to assess the status of the *EGFR* gene in gefitinib responders with NSCLC versus nonresponders (13–15). The results showed that gene amplification and balanced increase of *EGFR* and chromosome 7 (Chr7) were significantly correlated with response to TKIs. In addition, it has been shown that *HER2* gain also enhances the sensitivity to gefitinib therapy in NSCLC patients with *EGFR*-positive tumors (16).

The objectives of the present study were as follows: (*a*) to confirm the efficiency of FISH/chromogenic *in situ* hybridization (CISH) analysis in assessing *EGFR* and *HER2* in histologic biopsies and cytologic specimens of NSCLC and (*b*) to define in small-sized specimens the optimal scoring method of FISH or CISH for identifying NSCLC patients eligible for TKI treatment.

Materials and Methods

Patient and Tissue Samples

We obtained material from 42 NSCLC patients treated with gefitinib: 23 were biopsies and 6 were cytologic specimens (Table 1) obtained from our pathology department archives. For the remaining 13 tumors, we had paraffin blocks of surgical samples, and to reproduce the study procedure on small specimens, we prepared a tissue array (Advanced Tissue Arrayer model ATA-100, Chemicon International, Temecula, CA) taking two cores of 1 mm of diameter from one representative block. Eleven additional surgical samples were used as control for *in situ* hybridization procedures. Human tissue samples were used according to the guidelines of the local Ethics Committee.

All 42 patients had received compassionate therapy with gefitinib at the Oncology Division of San Giovanni Battista Hospital, Molinette (Turin, Italy; Table 2). Patients received 250 mg/d p.o. gefitinib for an indefinite period until disease progression or unacceptable toxicity. Objective tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (17). Duration of overall response was defined as the time from the date of the first objective assessment of a complete/partial response until the date of objectively documented progressive disease. Computed tomography of the chest and upper abdomen was done every 8 weeks. Survival and progression-free survival were defined as the period from the start of gefitinib treatment to the date of death or disease progression, respectively, or last follow-up.

DNA Extraction and PCR

Genomic DNA was extracted from four 10-μm-thick sections of formalin-fixed, paraffin-embedded blocks or alcohol-fixed, paraffin-embedded blocks. After deparaffinizing with xylene-ethanol, specimens were incubated overnight at 55°C in lysis buffer containing proteinase K (20 mg/mL) followed by DNA isolation after phenol-isopropanol extraction. DNA concentration was measured with a spectrophotometer (BioPhotomer, Eppendorf AG, Hamburg, Germany). The quality of DNA extracted from formalin-fixed, paraffin-embedded blocks or alcohol-fixed, paraffin-embedded blocks was tested by doing amplification of a 300-bp fragment of the human MHC class II DRβ gene with the following primers: 5′-CCGGTC-GACTGTCCCCCCAGCACGTTTC-3′ (DRBF) and 5′-GAATTCTCGCCGCTGCACTGTGAAGC-3′ (DRBR). PCR amplification of *EGFR* (exons 19 and 21) was done using the following primers: 5′-CAATATCAGCCTTAGG-TGCGGCTC-3′ (EGFR19F), 5′-CATAGAAAGTGAACATT-TAGGATGTG-3′ (EGFR19R), 5′-CTAACGTTCGCCAGC-CATAAGTCC-3′ (EGFR21F), and 5′-GCTGCGAGCTCA-CCCAGAATGTCTGG-3′ (EGFR21R). The primers were obtained from ref. 9.

Table 2. Characteristics of the 42 NSCLC patients

	Responder	Nonresponder	*P*
Patients, *n* (%)	12 (28.5)	30 (71.5)	
Median age, y (range)	60 (37–77)	63 (37–77)	
Gender, *n* (%)			
Female	9 (21.5)	5 (12)	0.0002
Male	3 (7)	25 (59.5)	
Age (y), *n* (%)			
<50	3 (7)	1 (2.5)	0.03
>50	9 (21.5)	29 (69)	
Stage, *n* (%)			
III	0	2 (5)	0.3
IV	12 (28.5)	28 (66.5)	
Previous radiotherapy lung	3	7	
Previous chemotherapy	11	28	
Previous surgery lung	3	10	
Site of disease			
Brain	4	6	
Bone	7	3	
Lung	9	18	

Table 3. Correlation of *EGFR* and *HER2* copy number to *EGFR* mutation and response to gefitinib

		EGFR disomy *HER2* disomy, *n* (%)	*EGFR* trisomy *HER2* disomy, *n* (%)	*EGFR* polysomy *HER2* disomy, *n* (%)	*EGFR* disomy *HER2* trisomy, *n* (%)	*EGFR* trisomy *HER2* trisomy, *n* (%)	*EGFR* polysomy *HER2* polysomy, *n* (%)	Total
Responder	*EGFR* mutated	0	0	1 (14)	0	1 (14)	5 (72)	7
	EGFR unmutated	2 (40)	0	0	0	1 (20)	2 (40)	5
Not responder	*EGFR* mutated	0	0	0	0	0	0	0
	EGFR unmutated	24 (80)	2 (7)	0	3 (10)	1 (3)	0	30
Total		26 (62)	2 (5)	1 (2.5)	3 (7)	3 (7)	7 (16)	42

PCR was done in a total volume of 50 μL containing 1× PCR buffer (20 mmol/L Tris-HCl, 50 mmol/L KCl), 1.5 mmol/L MgCl$_2$, 0.2 mmol/L deoxynucleotide triphosphates, 0.4 μmol/L each primer, 0.2 unit Taq DNA polymerase (Invitrogen, Carlsbad, CA), and 500 ng of genomic DNA. Thermal cycling conditions were as follows: 5 min at 94°C followed by 40 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for 30 s, with a final extension step of 72°C for 7 min.

DNA Sequencing

PCR products were separated on a 2% agarose gel, purified using the PCR Cleanup Gel Extraction kit (Macherey-Nagel, Dueren, Germany), and sequenced in both directions by dye terminator sequencing with the BigDye Terminator v1.1 Sequencing kit (Applied Biosystems, Foster City, CA). Sequencing fragments were detected by capillary electrophoresis on an ABI Prism 310 DNA analyzer (Applied Biosystems). In all cases, samples harboring mutations were subjected to a second round of amplification and sequencing. *EGFR* mutation analysis was done by laboratory personnel blinded to clinical response.

Fluorescence *In situ* Hybridization

Probes for *EGFR* (Vysis, Inc., Downers Grove, IL) and *HER2* (Vysis) were used for FISH according to the manufacturer's instructions. Briefly, sections were baked overnight at 56°C, deparaffinized in xylene, dehydrated in 100% ethanol, and air dried. Slides were pretreated in sodium thiocyanate for 30 min at 80°C and then with proteases for 7 to 10 min at 37°C; they were then washed in 2× SSC, air dried, covered with ~10 μL of probe (LSI *EGFR*/CEP7 dual-color probe or LSI *HER2*/CEP17 dual-color probe, Vysis), codenatured in HYBrite System (Vysis) for 5 min at 72°C, and hybridized overnight at 37°C with the probes. Finally, slides were washed with posthybridization buffer at 72°C and counterstained with 4′,6-diamidino-2-phenylindole. Tumor sections were first scanned at low power with a 4′,6-diamidino-2-phenylindole filter to identify areas of optimal tissue digestion and nonoverlapping nuclei. Analysis was done independently by two observers (A.S. and L.M.) blinded to the clinical response of the patients.

Chromogenic *In situ* Hybridization

Digoxigenin-labeled *EGFR* and *HER2* DNA probes (Zymed, South San Francisco, CA) and biotin-labeled centromeric probes for chromosome 17 (Chr17; Spot-Light Chr17 centromeric probe, Zymed) and Chr7 (Spot-Light Chr7 centromeric probe, Zymed) were used following the manufacturer's instructions. Sections were covered with coverslips and denatured on a hot plate at 94°C. Hybridization was done overnight at 37°C. Signals were detected using a CISH detection kit (Zymed). For *EGFR* and *HER2* tests, a peroxidase quenching solution was applied to the sections followed by nonspecific blocking solution for 10 min at room temperature, FITC-conjugated sheep anti-digoxigenin for 30 min at room temperature, horseradish peroxidase-goat anti-FITC for 30 min at room temperature, and 3,3′-diaminobenzidine chromogen for 30 min at room temperature. For biotin-labeled probes, horseradish peroxidase-streptavidin (30 min) followed by 3,3′-diaminobenzidine chromogen was used to reveal the reactions. Slides were counterstained with Mayer's hemalum. Genes and chromosomes, visualized as dark brown dots, were counted in parallel sections.

In situ Hybridization Categories and Statistical Analysis

FISH and CISH results for *EGFR* and *HER2* genes were assessed using the categories proposed by Hirsch et al. (18): balanced disomy (1.6–2.0 genes and chromosomes in all cells), balanced trisomy (2.2–3.0 genes and chromosomes in at least 10 cells), balanced polysomy (3.1–4.4 genes and chromosomes in at least 10 cells), low amplification (gene/chromosomes 2.1–3.0), and high amplification (gene/chromosomes >3). We considered as positive cutoff the presence of at least 10 neoplastic cells showing gene gain. The results were compared with those obtained on the whole sections, considering 40% of cells showing gene increase as cutoff. Clinical response was evaluated blinded to molecular results.

FISH/CISH analysis and clinical response to gefitinib were compared using the two-tail Fisher's exact test, and statistical significance was defined as $P < 0.05$. Statistical analyses were done using software freely available online.[4] The overall concordance between the different procedures was evaluated with K statistic. The Kaplan-Meier estimates of median time to disease progression (TTP) and overall survival (OS) of patients were analyzed.

---

[4] http://www.quantpsy.org

Figure 1. Exon 19 deletion E746-A750 of *EGFR* (**A**) and balanced polysomy (**B**) by dual-color FISH with probes for *EGFR* (*red*) and Chr7 (*green*). Deletion L747-P751insP of *EGFR* (**C**) and Chr7-*EGFR* trisomy (*brown spots*; **D**) by CISH. Deletion L747-A750 of *EGFR* (**E**) and balanced polysomy (**F**) by dual-color FISH with probes for *EGFR* (*red*) and Chr7 (*green*).

Results

The median follow-up for the patients who were still alive at the last follow-up was 14.8 months. The Kaplan-Meier estimates of median TTP for the overall population were 2.8 months. The median OS was 6 months. The 2-year survival rate was 12.5%.

EGFR Mutation Status

Among the 42 patients, 6 had a deletion in exon 19 (3 E746-A750, 1 L747-A750, 1 L747-P751insP, and 1 E746-P750insS) and 1 patient had the L858R missense mutation in exon 21. These seven patients with a mutated *EGFR* responded to gefitinib (100%); of the 35 patients without *EGFR* mutation, 14% responded to gefitinib ($P < 0.0001$; Table 3; Fig. 1A, C, and E). In mutated and unmutated

cases, neoplastic cells represented from 10% to 90% of cells on the slide sections.

EGFR and *HER2* Gene Copy Number

FISH analysis was successful in 37 of 42 cases; in the other 5 cases, CISH for genes and chromosomes was done (Table 1). The results obtained by tissue array, biopsy, and cytologic specimen showed good agreement with the result of full histologic analysis of surgical samples. Two cases showed balanced polysomy of *EGFR/HER2* in small specimens and high polysomy in full sections. The other cases showed balanced disomy for the two genes in both types of specimens.

None of the 42 cases analyzed by FISH (37 cases) or CISH (5 cases) showed amplification of either the *EGFR* or

Figure 2. Kaplan-Meier curves for TTP and OS. Median TTP was 16.7 mo for *EGFR* ≥3/*HER2* ≥3 and 2.3 mo for *EGFR* ≤2/*HER2* ≤2 patients ($P = 0.00014$). Median OS was 16.4 mo for *EGFR* ≥3/*HER2* ≥3 and 5.0 mo for *EGFR* ≤2/*HER2* ≤2 patients ($P < 0.00001$). Statistical significance of differences between the two groups was evaluated with log-rank tests.

HER2 gene. However, 16 cases (38%) presented a balanced gain of chromosomes and genes (Table 3). Specifically, Chr7-*EGFR* balanced polysomy was observed in eight cases (Fig. 1B and F) and balanced trisomy (Fig. 1D) in five. Chr17-*HER2* balanced trisomy was observed in six cases and balanced polysomy in seven. The *in situ* hybridization analysis subset was compared with mutation analysis and showed an overall concordance of 78.6% with a *k* value of 49% ($P < 0.001$; Table 3). In particular, Chr7-*EGFR* balanced polysomy was present in 6 of 7 (86%) mutated cases and in 2 of 35 (5.7%) unmutated cases. Chr7-*EGFR* balanced trisomy was present in 1 of 7 (14%) mutated cases and in 4 of 35 (11%) unmutated cases. Chr17-*HER2* balanced polysomy was present in 5 of 7 (71.4%) mutated cases and in 2 of 35 (6%) unmutated cases, whereas Chr17-*HER2* balanced trisomy was present in 14% of both mutated (1 of 7) and unmutated (5 of 35) cases (Table 3).

Seven cases (five mutated) with coupled *HER2/EGFR* balanced polysomy responded to gefitinib (mean TTP, 15.8 months; mean OS, 18.7 months) and one responder with Chr7-*EGFR* polysomy alone had a TTP and OS of 6.74 months. Two (one mutated) of three cases with *EGFR/HER2* trisomy had a clinical response to gefitinib but showed a TTP and OS similar to other five cases with balanced trisomy per single gene (three for *HER2* and two for *EGFR*) that did not respond (mean TTP, 2.4 months; mean OS, 8.38 months).

In conclusion, 10 of 13 (77%) patients with genomic gain of *EGFR* and 9 of 13 (69%) cases with genomic gain of *HER2* responded to gefitinib compared with 2 of 29 (6.8%) and 3 of 29 (10%) balanced disomic cancers, respectively ($P < 0.0001$ and 0.0005; Table 3; Fig. 2). The score categories for FISH/CISH results in small specimens considered as positive, doubtful, or negative responders to gefitinib are reported in Fig. 3.


Figure 3. Diagnostic interpretation of *EGFR* and *HER2* gene gain by FISH/CISH in small specimens of NSCLC.

Discussion

The principal findings of this study are the following: (*a*) the results of FISH/CISH analysis done on small-sized specimens represent a successful method for establishing the *EGFR/HER2* gene content in NSCLC; (*b*) as reported in the literature, gain of *EGFR* and *HER2* genes is more frequently a consequence of Chr7 and Chr17 polysomy, respectively, rather than gene amplification; and (*c*) concurrent polysomy and, less specifically, concurrent trisomy of *EGFR* and *HER2* may be considered as positive markers for selecting NSCLC patients eligible for TKI treatment.

The first aim of our study was to validate the *EGFR/HER2* gene study by FISH or CISH in very small tissue samples of lung cancers. In our series, in 68% of cases, the first diagnosis of NSCLC was obtained from small biopsies or cytologic samples. This limited the possibility of characterizing the histotype of tumors in 7% of cases. Several studies have reported successful use of FISH and CISH in alcohol-fixed fine-needle aspiration cytology or tissue array (19–22). In this study, either FISH or CISH was successful in all specimens analyzed. The use of CISH to enumerate both genes and chromosomes was limited to samples that were difficult to interpret by fluorescence microscopy because of highly heterogeneous cell populations (pleural effusion or bronchial lavage) or high autofluorescent background due to hemosiderin or necrosis.

The second aim was to define, when dealing with small tissue specimens analyzed by FISH/CISH, the diagnostic criteria useful for selecting patients with NSCLC who are eligible for TKI treatment. To this end, a Medline search was done using as query term ''EGFR and gene number and lung'' (Supplementary Table S4),[5] and we selected eight studies that used FISH to evaluate the status of the *EGFR* gene with or without correlation to mutations and clinical response (13, 14, 18, 23–27). First, the literature confirms that gain of *EGFR* according to FISH correlates with gene mutation (13, 27). However, these results cannot be interpreted in a straightforward manner because FISH positivity or negativity is variably defined (14, 26, 27). *EGFR* amplification by FISH has been reported in ∼10% of NSCLC (13, 18, 24, 25), but balanced trisomy (three copies of the gene and Chr7) and polysomy (four or more copies of the gene and Chr7) are the most frequent events leading to *EGFR* gain. In large case series of NSCLC, trisomy or polysomy is further subdivided into ''low'' or ''high'' depending on the cutoff of 40% of cells showing three or four or more copies of *EGFR* and Chr7 (13). As recently discussed in the article by Dziadziuszko et al. (8), the use of this cutoff even in high polysomy does not exclude that there may be plenty of diploid cells. Thus, the risk of underestimating FISH results has to be taken into account when dealing with small, paucicellular

specimens. Our data show that, in small samples, any gene gain of *EGFR* and *HER2* in 10 neoplastic cells is comparable with the 40% cutoff in tumor surgical samples and correlates with the presence of specific mutations in the *EGFR* gene. In addition, although *EGFR* gene copy number detected by FISH is associated with improved response to gefitinib (13–15), conflicting results are reported on the role of *HER2* gene gain (14, 16). As previously reported (16) we confirmed that only concurrent gain of both *HER2* and *EGFR* genes is associated with sensitivity to gefitinib.

In conclusion, because none of the clinical predictors, such as smoking status, race, patient sex, and histology, could guarantee or exclude clinical benefit from gefitinib, molecular factors may be incorporated to define the probability of response to TKIs. However, to prevent incompatibility in techniques and interpretation, we suggest that, for endoscopic biopsies or cytologic specimens, FISH/CISH analysis may be used as the first-choice laboratory test as an alternative to gene mutation analysis. The probability of response will be lower in cases without *EGFR* and *HER2* gene gain.

References

1. Engelman JA, Cantley LC. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006;12:S4372–6.

2. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550–65.

3. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy. Cancer Res 2002;62:5749–54.

4. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19: 3267–79.

5. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7: 2958–70.

6. Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 2004;46:247–54.

7. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103–9.

8. Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn PA, Jr. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence *in situ* hybridization—why, when, and how? Clin Cancer Res 2006;12: 4409–15s.

9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.

10. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from ''never smokers'' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306–11.

11. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497–500.

12. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006;354:526–8.

13. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643–55.

---

[5] Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

14. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence *in situ* hybridisation associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838 – 45.

15. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23: 6829 – 37.

16. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005;23:5007 – 18.

17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205 – 16.

18. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798 – 807.

19. Beatty BG, Bryant R, Wang W, et al. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence *in situ* hybridization and immunocytochemical analysis. Am J Clin Pathol 2004;122:246 – 55.

20. Sumiyoshi K, Shibayama Y, Akashi S, et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections? Oncol Rep 2006;15:803 – 8.

21. Sapino A, Marchio C, Senetta R, et al. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch 2006;449:288 – 96.

22. Halling KC, Rickman OB, Kipp BR, Harwood AR, Doerr CH, Jett JR. A comparison of cytology and fluorescence *in situ* hybridization for the detection of lung cancer in bronchoscopic specimens. Chest 2006;130: 694 – 701.

23. Al-Kuraya K, Siraj AK, Bavi P, et al. High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Hum Pathol 2006;37:453 – 7.

24. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer— molecular and clinical predictors of outcome. N Engl J Med 2005;353: 133 – 44.

25. Dacic S, Flanagan M, Cieply K, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 2006;125:860 – 5.

26. Willmore-Payne C, Holden JA, Layfield LJ. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. Hum Pathol 2006;37: 755 – 63.

27. Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphoryla-tion. Clin Cancer Res 2006;12:2538 – 44.

AACR American Association for Cancer Research

Molecular Cancer Therapeutics

Predicting gefitinib responsiveness in lung cancer by fluorescence *in situ* hybridization/chromogenic *in situ* hybridization analysis of *EGFR* and *HER2* in biopsy and cytology specimens

Lorenzo Daniele, Luigia Macrì, Marina Schena, et al.

Updated version	Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-06-0719

Cited articles	This article cites 27 articles, 11 of which you can access for free at: http://mct.aacrjournals.org/content/6/4/1223.full#ref-list-1
Citing articles	This article has been cited by 7 HighWire-hosted articles. Access the articles at: http://mct.aacrjournals.org/content/6/4/1223.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/6/4/1223. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.